Merck-Moderna vaccine cuts odds of skin cancer recurrence in half, study finds
CBSN
A vaccine shows promising results in treating the most deadly form of skin cancer, Moderna and Merck announced on Thursday.
Those with severe melanomas who received the vaccine and Merck's cancer drug Keytruda were 49% less likely to die or have their cancer come back after three years than those who were given only Keytruda, the biotech companies said in a news release.
The companies have begun Phase 3 trials of mRNA-4157 with Keytruda, given a breakthrough therapy designation by the Food and Drug Administration earlier this year. The designation is meant to expedite the development and review of drugs meant to treat life-threatening diseases.
Washington — The Supreme Court on Friday said it will consider the constitutionality of the Federal Communications Commission's Universal Service Fund, agreeing to review a lower court decision that upended the mechanism for funding programs that provide communications services to rural areas, low-income communities and schools, libraries and hospitals.
Jeff Bezos' Blue Origin launched six space tourists on a high-speed dash to the edge of space and back Friday, giving the passengers — including a husband and wife making their second flight — about three minutes of weightlessness and an out-of-this world view before the capsule made a parachute descent to touchdown at the company's west Texas flight facility.